Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian Rx Imports Would Supply 10% Of U.S. Market, Caremark Exec Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The limited supply of drugs coming from Canada under a legalized importation system would have little impact on U.S. prices, Caremark CEO Crawford says at PCMA annual meeting. Importation would require PBMs to decide how to distribute lower-priced Canadian products among their clients, he says.

You may also be interested in...



HDMA Sees Reimportation In 2005 Regardless Of Presidential Election Results

Rx importation will "come to pass one way or another," Healthcare Distribution Management Association CEO John Gray says. An association-commissioned report is designed to demonstrate the value of distributors in the pharmaceutical supply chain.

Rx Imports Could Be "Good For The Country," Caremark Suggests

Caremark sees the potential for legalized wholesale imports from Canada to offer an opportunity analogous to the current profit and savings impact of generic drugs

Drug Importation Infrastructure Already Largely In Place, CVS CEO Says

A bulk importation scheme through certified foreign exporters would require adding safeguards to the existing U.S. distribution system, CVS CEO Ryan tells the HHS importation task force. Primary importation challenge would be ensuring adequate supply

Related Content

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel